Switzerland
Charles River Ventures backs ProtonMail
Email encryption service raises $2m from US-based VC
Sunstone leads €8.7m Prexton Therapeutics round
Ysios Capital and MS Ventures also take part in series-A
Redalpine backs CHF 4.5m easySYS round
Swiss VC firm invests alongside family office Armada
EQT in SEK 1.94bn final exit from Sanitec
GP sells 20% stake held since 2013 IPO
Swiss currency move: the potential impact on private equity
Cap removal does not lead to loss of interest
VC backers divest GlycoVaxyn to GSK
Deal values biopharmaceutical company at $212m
Bridgepoint sells Infront to Wanda for €1.05bn
Deal value understood to be 11.9x EBITDA, generating 37% IRR for Bridgepoint
LGT's Crown Co-investment Opportunities fund holds final close
Vehicle has already completed 11 co-investments
CVC-backed Sunrise lists in €3.06bn IPO
IPO is the largest in Switzerland since 2006, with €3.06bn market cap
SHS backs AOT
Growing market for robot-guided surgical systems prompts investment
Equistone divests avocis to Capita for €210m
Capita to use acquisition to grow its business in DACH region
Unigestion's Engler joins Axon
Placement agent appoints Mark Engler as partner in its Zug office
Akina closes Euro Choice Secondary on €224m
Fund launched in Q4 2013 with €200m target
DACH region suffers activity slump in 2014
DACH deal volume has dropped to its lowest position since 2002
Adveq promotes four to executive director
Fund-of-funds manager Adveq announces promotions
Auctus closes fourth fund on €230m
Latest vehicle oversubscribed in less than three months
NeoMed leads CHF 20m Genkyotex financing
VI Partners and BioMedInvest are co-investors
SPFS acquires APEN portfolio for $192m
APEN also sells entire loan obligation and deleverages
Apax sells Orange Switzerland to NJJ for €2.3bn
Sale comes after three-year holding period
Versant closes fund on $305m, makes European promotions
Principal Tom Woiwode has been promoted to managing director in firm's Basel office
Rive buys Parquest's 5aSèc
Shareholders have injected €10m fresh equity into company
Zurmont Madison sells CLS for $77m
Exit comes after five-year holding period
Parter Capital injects CHF 4.5m into Histide
Private equity house specialises in research-based investments
Molecular floats with CHF 482m market cap
Shares dropped to CHF 22.4 within hours, having opened on CHF 25